Afovirsen

An antisense oligonucleotide drug

Afovirsen
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number
PubChem
DrugBank
ChemSpider
KEGG

Afovirsen is an antisense oligonucleotide drug that was developed for the treatment of cytomegalovirus (CMV) infections. It is designed to inhibit the replication of CMV by binding to the viral mRNA and preventing the production of essential viral proteins.

Mechanism of Action

Afovirsen works by targeting the mRNA of the cytomegalovirus. As an antisense oligonucleotide, it binds specifically to the complementary sequence of the viral mRNA. This binding results in the degradation of the mRNA or the inhibition of its translation, thereby preventing the synthesis of viral proteins necessary for the replication of the virus.

Development and Clinical Use

Afovirsen was developed as a therapeutic agent for patients with CMV infections, particularly in immunocompromised individuals such as those with HIV/AIDS or undergoing organ transplantation. The drug was designed to offer a targeted approach to inhibit viral replication with potentially fewer side effects compared to traditional antiviral drugs.

Pharmacokinetics

The pharmacokinetics of afovirsen involve its distribution, metabolism, and excretion in the body. As an oligonucleotide, it is typically administered via injection. The drug is designed to be stable in the bloodstream and to reach the target cells where CMV replication occurs.

Side Effects

Like many antiviral agents, afovirsen may have side effects. These can include local reactions at the site of injection, as well as systemic effects such as fever, fatigue, and gastrointestinal disturbances. The specific side effect profile of afovirsen would depend on the dosage and the individual patient's response to the drug.

Related pages

• Antisense therapy
• Cytomegalovirus
• Antiviral drug
• Oligonucleotide

• 
  Chemical structure of Afovirsen